Zhao Xuemiao, He Haijun, Xiong Xi, Ye Qianqian, Feng Feifei, Zhou Shuoting, Chen Weian, Xia Kai, Qian Shuangjie, Yang Yunjun, Xie Chenglong
Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Front Aging Neurosci. 2022 May 12;14:869797. doi: 10.3389/fnagi.2022.869797. eCollection 2022.
To explore the combined diagnostic value of plasma Lewy body-associated proteins (p-Asyn at ser129, total α-syn, and oligomeric α-syn) for the diagnosis of PD versus healthy controls (HCs) and other PD syndromes (PDs), as well as clinical characteristics prediction.
This study included 145 participants: 79 patients with PD, 24 patients with PDs, and 42 HCs. A panel of plasma levels of p-Asyn, total α-syn, and oligomeric α-syn was measured by enzyme-linked immunosorbent assay (ELISA). The primary outcome was the discriminative accuracy of the combined three plasma biomarkers for PD.
The mean age was 65.43 (SD, 7.467) in the control group, 64.49 (SD, 8.224) in participants with PD, and 69.25 (SD, 7.952) in PDs. The plasma Lewy body-associated protein levels were significantly higher in patients with PD than in age-matched HCs, However, there was no difference in patients with PD and PDs. Of note, a combination of plasma p-Asyn, total α-syn, and oligomeric α-syn was a better biomarker for discriminating PD from HCs, with an AUC of 0.8552 ( < 0.0001, 95%CI, 0.7635-0.9409), which was significantly higher than plasma p-Asyn (ΔAUC, 0.1797), total α-syn (ΔAUC, 0.0891) and oligomeric α-syn (ΔAUC, 0.1592) alone. Meanwhile, Lewy body-associated proteins had no connections between different motor stages and dementia performances.
Our results suggested that plasma Lewy body-associated proteins, may serve as a non-invasive biomarker to aid the diagnosis of PD from HCs. In addition, increased plasma Lewy body-associated proteins were not associated with the progression of motor and non-motor symptoms.
探讨血浆路易小体相关蛋白（丝氨酸129位点的磷酸化α-突触核蛋白、总α-突触核蛋白和寡聚化α-突触核蛋白）对帕金森病（PD）与健康对照（HCs）及其他帕金森综合征（PDs）的联合诊断价值，以及对临床特征的预测作用。
本研究纳入145名参与者：79例帕金森病患者、24例帕金森综合征患者和42名健康对照者。采用酶联免疫吸附测定（ELISA）法检测血浆中磷酸化α-突触核蛋白、总α-突触核蛋白和寡聚化α-突触核蛋白水平。主要结局是三种血浆生物标志物联合检测对帕金森病的鉴别准确性。
对照组的平均年龄为65.43（标准差，7.467），帕金森病患者为64.49（标准差，8.224），帕金森综合征患者为69.25（标准差，7.952）。帕金森病患者血浆路易小体相关蛋白水平显著高于年龄匹配的健康对照者，然而，帕金森病患者与帕金森综合征患者之间无差异。值得注意的是，血浆磷酸化α-突触核蛋白、总α-突触核蛋白和寡聚化α-突触核蛋白联合检测是区分帕金森病与健康对照者的更好生物标志物，曲线下面积（AUC）为0.8552（P<0.0001，95%置信区间，0.7635 - 0.9409），显著高于单独的血浆磷酸化α-突触核蛋白（ΔAUC，0.1797）、总α-突触核蛋白（ΔAUC，0.0891）和寡聚化α-突触核蛋白（ΔAUC，0.1592）。同时，路易小体相关蛋白与不同运动阶段和痴呆表现之间无关联。
我们的结果表明，血浆路易小体相关蛋白可能作为一种非侵入性生物标志物，有助于帕金森病与健康对照者的诊断。此外，血浆路易小体相关蛋白升高与运动和非运动症状的进展无关。
